Mirati Therapeutics, Inc.
MRTX
शेयरों में रैंक
#4928
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
शेयर मूल्य
$58.70
अंतिम समन्वयन: 2024-01-23
मार्केट कैप
$2.98B
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार Mirati Therapeutics, Inc. (MRTX)
श्रेणी
Healthcare
Mirati Therapeutics, Inc. (MRTX) के लिए EPS
2026 TTM तक का EPS: 0
Mirati Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्टों और शेयर मूल्य के अनुसार, कंपनी का वर्तमान EPS (TTM) 0 है। 2026 के अंत में, कंपनी का EPS 0 था, जो 2026 के EPS 0 के के बराबर था।
Mirati Therapeutics, Inc. के लिए 2026 से 2026 तक का EPS इतिहास
प्रत्येक वर्ष के अंत में EPS
| वर्ष | EPS | परिवर्तन |
|---|---|---|
| प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं। | ||
समान कंपनियों या प्रतिस्पर्धियों के लिए EPS
| कंपनी | EPS | EPS अंतर | देश |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
